Contact the Complete Laboratory Supplier Labware Supplies: Branches: Palmerston North, P.O
Total Page:16
File Type:pdf, Size:1020Kb
Reflotron!System The new concept in real-time-analysis BOEHRINGER MANNHEIM NZ LTD. P.O. BOX 62-089, MT WELLINGTON, AUCKLAND Telephone: 276-4157 or Circle 1 on Readers Reply Card SONATEC SYSTEMS LTD, PO. BOX 78096, 4 MURDOCK ST. GREY LYNN , AUCKLAND 2. TELEPHONE (09) 764-533, TELEX NZ21710 Automated Clinical Chemistry Systems Immuno-Chemistry Systems Electrophoresis Systems Stand Alone Analysers Universal Clinical Reagents SONATEC SYST EMS LTD are pleased to announce that we have been appointed exclusive agent in New Zealand for BECKMAN DIAGNOSTIC PRODUCTS For further information, please contact JOCK LECHTENBORGER OR MALCOLM DEAN TELEPHONE (09) 764-533 or Circle 14 on Readers Reply Card When you mention Take the Enzygnost!tests for example, progressive diagnostic a part of the world wide success of the systems, you're really Behring ELISA System talking about Behring Enzygnost, the widest range Enzygnost HBsAg) micro, of ELISA-tests in medical Enzygnost Anti-HBs, microbiology, is the sum of Enzygnost Anti-HBc, Enzygnost Anti-HBc (lgM*) easy handling Enzygnost HBe, reliab il ity Enzyg nost Anti-HTLV Ill compactness Enzygnost Rube ll a, high throughput Enzygnost Rotavi rus (Ag), high specificity and Enzygnost Anti-Cytomega sensitivity loviru s, • automatisation Enzygnost Anti-HSV, realized in divisible Enzygnost Varicella/Zoster, microtitration plates Enzygnost Toxoplasmosis (lgG), Enzygnost Measles, Enzygnost Parotiti s, Enzygnost Aujeszky, Enzygnost Bovine Leucosis, Enzygnost IBR/IPV * available soon m (!) Behring Diagnostics Section. (!) (!) Hoechst New Zealand Limited BEHRING 0 or Circle 6 on Readers Reply Card "'0 C.P.O. Box 67 Auckland .r:: -!~ _J Phone 578-068. Telex 2338 THE NEW ZEALAND JOURNAL OF ~~wrr~ ~@~JJ@~W u~~rnr~@OO@W Vol.40 No.4 November 1986 ISSN 0028-8349 TABLE OF CONTENTS Original Articles The Anti-Streptolysin 0 Test- Survei ll ance of Current Laboratory Practice in New Zealand D. R. Martin, H. Brady . .......................... ............. ................... ......................... 160 HPLC Determination of Amiodarone and its Metabolite Desethylamiodarone in Plasma and Erythrocytes R. W. L. Siebers, C. T. Chen, T. J. B. Maling . ...................... ......... 162 Silver Jubilee of the Auckland Hospital Board School of Medical Laboratory Technology, 1961-86 M. J. Grey .... .... .... .. .. ..... ..... ... ...... ........ .. ... ... .. ....... .. ... ... .. ... .. .. ...... ...... ............... 164 Technical Communication Evaluation of Biorad Quantaphase B, 2 and Folate Kit S. Chambers, M. Hallowes ... ......... .................... .. 166 The Pacific Way N.Z. Microbiology Society: 30 Year On ...... 169 Annual Staffing Survey . .................................. .. .. .. -· .1 84 42nd AGM/SGM . .. 187 Institute Business ...... 188 Situations Vacant ... 193 Coming Events .. .. .... 189 Work Wanted .................... 193 New Products and Services ................................ 190 Subscriptions to the Journal for non-members Intending contributors should submit their material to the requiring delivery in New Zealand is $NZ30.00 for 1 Editor, D. Dixon-Mclver, Biochemistry Laboratory, National year surface mail paid. Single issues are $NZ1 0.00 Women's Hospital, Auckland, New Zealand, or The Editor, surface mail paid. P.O. Box 35-276, Auckland 10, New Zealand. Acceptance Subscription to the Journal for non-members is at the discretion of the Editor, and no undertaking is given requ iring delivery overseas is $NZ30.00 for 1 year that any article will be published in a particular issue. The plus $NZ4.20 surface mail paid. All subscriptions copy deadline for each issue is the first of the month prior to except for sin gle issues are due in February. the month of publication. ADVERTISER INQUIRIES Inquiries regarding advertising rates and copy or blocks DIRECTIONS FOR CONTRIBUTORS for advertising should be addressed to the Advertising From Vol. 36 No. 1 all papers published will be in the form Manager, Trish Reilly, 48 Towai St, St Heliers, Auckland 5, known as "Vancouver Style" or Uniform Requirements for Phone 555-057. Manuscripts submitted to Biomedical Journals. Fu ll details may be found in the New Zealand Journal of Medical DATES OF PUBLICATION Laboratory Technology, Vol. 36, No.4, page 90 to 109 or The months of publication for 1986 are March, May, from the Editor. August and November. This Journal is abstracted by : Biological Abstracts, Chemical Abstracts, Cumulative Index Nursing and Allied Health Literature, Current Clinical Chemistry, Hospital Abstracts , lnstitut nautchnoi informatsii. Contributions to the Journal do not necessarily reflect the views of the Editor, nor the policy of the Council of the Institute. 160 N.Z. J. Med. Lab. Techno/., 1986 The Anti-Streptolysin 0 Test - Surveillance of Current Laboratory Practice in New Zealand Diana R. Martin and Helen Brady National Health Institute, Kenepuru, Wellington Introduction Buffer: Streptolysin 0 is one of a num ber of extracell ular antigens Herbert and Todd8 showed haemolytic activity of streptolysin expressed during infection with groups A and C streptococci. 0 to be maximal at pH 6.5. To eliminate effects of streptococcal The respondin g antibody, anti-streptolys in 0 (ASO) can be proteases present in preparations either gelatin or bovi ne serum measured in patients' serum and its elevation provides evidence albumin may be utilised in the buffer. 9.1oThese components also of recent streptococcal infection., retard spontaneous lys is of erythrocytes. The components of The most widely employed method of testing for ASO is the manufactured buffers are unknown in most cases. Eight neutralisation test, also known as the haemolytic test. In th is test laboratories reported that the buffer used is their own two important properties of streptolysin 0 are utilised. preparation. Six use phosphate buffered sal ine, pH 6.5-6.6, and Streptolysin 0 is an oxygen-labile haemolysin able to combine two use gelatin-barbitone buffer, pH 7.2. Twenty-two with and be neutralised by ASO regardless of its oxidative state laboratories do not pH their commercial buffer. Of the five that but which is haemolyticall y active onl y in its reduced form.2 The do, four are using a commercial buffer with pH 6.5 and one a ASO test measures the ability of a serum to combine with and commercial buffer with pH 7.2. It is noted that at least two thus inhibit the haemolytic activity of a standard concentration of manufacturers imply implicit trust in their product as no pH value reduced streptolysin 0. 1 is given on product sheets for users to verify. Since its development by Todd,1 modifications of the tube haemolytic test have included microtitration3 and the utilisation Anti-streptolysin 0 standard: of a patient's whole blood.4 Alternative types of test not involvi ng Two laboratories reported no reference standard control the haemolytic property of streptolysin 0 include a single rad ial serum is used with their test. Six laboratories use either a known immunodiffusion tests and particle agg lutination testsN In the positive patient's serum or pooled positive sera and one of these latter streptolysin 0 is coated onto particles such as latex, treated also controls with a commercial standard serum. All other erythrocytes or certain bacteria l cell s. laboratories use a commercial standard. In 1980 all hospital and private medical diagnostic laboratories Validity of resu lts is dependent on the use of a control serum of likely to be undertaking ASO testing were surveyed to determine known titre as provided by the ASO standard.,, This standard what methods were being used. This exercise was repeated in provides a qual ity check on the performance of the reagents. If 1986 to assess the impact of a changing technology. The resu lts the titre check of the reference serum differs at all from the obtained have provided the stimulus for th is paper, wh ich seeks expected va lue, it is necessary to repeat the whole test. to inform laboratories about the critical components of the test. Commercially available ASO control sera are standardised by titration against the World Health Organisation International Results Standard for ASO to give a precise titre as quoted by th e Response rate for the questionnaire in 1980 was 76.6% (49/64) manufacturer for specific test conditions.1 2 Furthermore and in 1986 was 82.0% (50/61). Thirty-six responding streptolysin 0 is standardised for the test such that one unit of laboratories undertook ASO titrations in 1980 and 38 in 1986. The streptolysin 0 is completely neutrali sed by one anti-streptolysin remaining responders referred sera to other laboratories fo r 0 unit. testing. The numbers of tests being performed, based on an Red blood cells (RBC): approximated monthly average, has not changed noticeably. In The original haemolytic test as described by Todd used rabbit 1980 hospital laboratories averaged per month 22 tests and RBC. Modifications since then have been to use sheep, 13 horse,14 private laboratories 120 tests, and in 1986 averages were 28 and and human.1s Some commercial kits recommend human as an 112 respectively. alternative to rabbit erythrocytes when using the tube technique. Of the 38 laboratories undertaking ASO tit rations 35 are using Tit res can be affected by the use of human RBC in microtitration the haemolytic test and three latex agg lutination. Only one because of adherence to the sides of U plate wel ls causing laboratory recorded a change from the haemolytic test to latex difficu lty in interpretation of the